<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29456563</article-id><article-id pub-id-type="pmc">5813291</article-id><article-id pub-id-type="publisher-id">JRMS-23-6</article-id><article-id pub-id-type="doi">10.4103/jrms.JRMS_218_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Does topical tranexamic acid reduce postcoronary artery bypass graft bleeding?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mirmohammadsadeghi</surname><given-names>Amir</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mirmohammadsadeghi</surname><given-names>Mohsen</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Kheiri</surname><given-names>Mahnaz</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1">Department of Cardiovascular Surgery, Chamran Hospital, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Department of Cardilogy, Islamic Azad University Najafabad Branch, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mohsen Mirmohammadsadeghi, Chamran Heart Center, Moshtagh Sevvom, Isfahan, Iran. E-mail: <email xlink:href="mohsenmirmohamadsadeghi@gmail.com">mohsenmirmohamadsadeghi@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2018</year></pub-date><volume>23</volume><elocation-id>6</elocation-id><history><date date-type="received"><day>17</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>16</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2018 Journal of Research in Medical Sciences</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Postoperative bleeding is a common problem in cardiac surgery. We tried to evaluate the effect of topical tranexamic acid (TA) on reducing postoperative bleeding of patients undergoing on-pump coronary artery bypass graft (CABG) surgery.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>One hundred and twenty-six isolated primary CABG patients were included in this clinical trial. They were divided blindly into two groups; Group 1, patients receiving 1 g TA diluted in 100 ml normal saline poured into mediastinal cavity before closing the chest and Group 2, patients receiving 100 ml normal saline at the end of operation. First 24 and 48 h chest tube drainage, hemoglobin decrease and packed RBC transfusion needs were compared.</p></sec><sec id="st3"><title>Results:</title><p>Both groups were the same in baseline characteristics including gender, age, body mass index, ejection fraction, clamp time, bypass time, and operation length. During the first 24 h postoperatively, mean chest tube drainage in intervention group was 567 ml compared to 564 ml in control group (<italic>P</italic> = 0.89). Mean total chest tube drainage was 780 ml in intervention group and 715 ml in control group (<italic>P</italic> = 0.27). There was no significant difference in both mean hemoglobin decrease (<italic>P</italic> = 0.26) and packed RBC transfusion (<italic>P</italic> = 0.7). Topical application of 1 g TA diluted in 100 ml normal saline does not reduce postoperative bleeding of isolated on-pump CABG surgery.</p></sec><sec id="st4"><title>Conclusion:</title><p>We do not recommend topical usage of 1 g TA diluted in 100 ml normal saline for decreasing blood loss in on-pump CABG patients.</p></sec></abstract><kwd-group><kwd>Administration</kwd><kwd>coronary artery bypass</kwd><kwd>postoperative hemorrhage</kwd><kwd>topical</kwd><kwd>tranexamic acid</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Diffuse bleeding is a common problem after cardiac operations using cardiopulmonary bypass (CPB). CPB causes platelet dysfunction, decreased clotting factors, and fibrinolysis.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] Significant fibrinolysis after CPB is reflected by increased concentrations of plasmin and fibrin degradation products.[<xref rid="ref4" ref-type="bibr">4</xref>] Nearly 2%&#x02013;6% of patients need re-exploration for excessive mediastinal bleeding after coronary artery bypass graft (CABG) surgery[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] which is responsible for 10.3% of all CABG surgery deaths. Almost 25%&#x02013;40% of significant postbypass bleedings are caused by fibrinolysis.[<xref rid="ref8" ref-type="bibr">8</xref>] There are several antifibrinolytic drugs such as aminocaproic acid,[<xref rid="ref9" ref-type="bibr">9</xref>] aprotinin,[<xref rid="ref10" ref-type="bibr">10</xref>] and tranexamic acid (TA).[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] Their systemic usage has been shown to reduce postbypass bleeding but may be associated with thromboembolic complications and early graft closure.[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] There are some different reports of topical TA usage for reduction of postbypass bleeding.[<xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>] We tried to include a larger number of patients to evaluate topical TA effect on postoperative bleeding of on-pump CABG patients.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Study design</title><p>This study was randomized and double-blinded clinical trial; questionnaires were filled by different personnel in intensive care unit (ICU) and operating room, and the surgeon was not aware of it. Patients who received TA therapy (intervention group) were compared to patients who used normal saline therapy (control group). Inclusion criteria were patients undergoing CABG surgery alone, interrupting aspirin 3 days[<xref rid="ref18" ref-type="bibr">18</xref>] and Plavix at least 5 days before surgery, lack of consuming any other anticoagulant drugs such as heparin or warfarin, lack of coagulation and bleeding disorders, and lack of liver and kidney disease.[<xref rid="ref20" ref-type="bibr">20</xref>] Exclusion criteria were complex surgery, emergency surgery, anticoagulation therapy before surgery, and having hemoglobin lower than 8 g per deciliter before surgery. Written consent form was obtained from patients. This study was registered with IRCT2016071628945N1q number.</p><p>One hundred and twenty-six patients undergone CABG, who had been diagnosed by a cardiologist and based on inclusion and exclusion criteria were included in the study. The patients were divided into two groups of intervention and control (63 cases in control group and 63 cases in intervention group). One hundred and twenty-five patients completed the study; 62 from TA group and 63 from normal saline group. Random assignment was performed by dividing patients into even and odd year of birth; even years were intervention group and odd years were control group [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Patient enrollment flowchart</p></caption><graphic xlink:href="JRMS-23-6-g001"/></fig><p>The anesthetic management and conduct of CPB were standardized. The patients were premedicated using nitrazepam 0.1 mg/kg tablet the night of the operation and morphine 0.15 mg/kg intramuscular &#x000bd; h before operation. Induction was done using fentanyl 2&#x02013;5 ug/kg, propofol 1&#x02013;2 mg/kg, and pancuronium 0.1 mg/kg. Anesthesia was maintained using sevoflurane 0.5%&#x02013;1%, pancuronium 0.06 mg/kg, and fentanyl 1&#x02013;2 ug/kg during CPB time. All patients received heparin 300 units/kg before CPB to achieve target activated clotting time (ACT) of &#x02265;480 s. During CPB, extra heparin was given as needed to maintain the target ACT.[<xref rid="ref20" ref-type="bibr">20</xref>]</p><p>After completion of the operation and suction all fluids and blood in the wound, for intervention group, TA (TRANEXIP, Capiantamin Company) with dose of 1 g diluted in 100 mL of saline, and for the control group, 100 mL of saline was poured into pericardial space and then the chest tube was clamped and the wound was closed and the patient was transferred to the ICU and then chest tubes were opened. The primary outcome measure for our study was the 1<sup>st</sup> day bleeding amount in the chest bottle, total amount of bleeding in 48 h, and the amount of blood transfusion. Two different technicians collecting the same data separately and the surgeon were not informed about the groups.</p></sec><sec id="sec2-2"><title>Statistical analysis</title><p>Analysis was done using descriptive statistics such as mean and standard deviation and analytical statistics such as <italic>t</italic>-test, Mann&#x02013;Whitney test, and Pearson and Spearman correlation coefficient by SPSS software version 22. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Both groups were matched in terms of age (<italic>P</italic> = 0.585) and gender (<italic>P</italic> = 0.66) [<xref ref-type="table" rid="T1">Table 1</xref>]. One patient was dropped out and finally, 125 patients completed the study. The age range of patients in the intervention group was 41&#x02013;79 years and control group 40&#x02013;78 years. In intervention group, 77.8% (<italic>n</italic> = 49) of patients were male and in control group was 81% (<italic>n</italic> = 51). Moreover, serious adverse event were not observed in both groups.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic data of the study sample</p></caption><graphic xlink:href="JRMS-23-6-g002"/></table-wrap><p>Furthermore, body mass index (BMI) and ejection fraction [Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>] did not show a significant differences between the groups (<italic>P</italic> = 0.188 and <italic>P</italic> = 0.463, respectively). As obtained, clamp time was significantly more in intervention group as compared to control group (56.66 vs. 49.46 min) (<italic>P</italic> = 0.01). Surgery duration and bypass time in both groups were same to each other and no differences were obtained (<italic>P</italic> = 0.257 and <italic>P</italic> = 0.166, respectively).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Results of the study sample</p></caption><graphic xlink:href="JRMS-23-6-g003"/></table-wrap><p>In <xref ref-type="table" rid="T2">Table 2</xref>, it is shown that the mean of bleeding amount in first 24 h after surgery in intervention group was 567.42 ml and in control group was 564.44 ml (<italic>P</italic> = 0.894). Moreover, the mean of bleeding amount in second 24 h after surgery and totally in intervention group was 213.07 ml and 780.48 ml, respectively, and in control group was 155.71 ml and 665.4 ml, respectively (<italic>P</italic> = 0.327 and <italic>P</italic> = 0.033, respectively); it shows that the amount of bleeding had no statistically difference in both groups. Furthermore, the mean of blood transfusion and hemoglobin decreasing did not show a significant correlation between the groups (<italic>P</italic> = 0.708 and <italic>P</italic> = 0.263, respectively).</p><p>As obtained, the risk factors for massive bleeding in patients undergoing CABG surgery were BMI (correlation coefficient = &#x02212;0.239, <italic>P</italic> = 0.007), clamp time (correlation coefficient = 0.213, <italic>P</italic> = 0.018), and surgery duration (correlation coefficient = 0.292, <italic>P</italic> = 0.001), which shows that BMI had reverse correlation with bleeding volume, whereas clamp time and surgery duration had positive and significant correlation with bleeding volume.</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Intravenous use of TA has proved to be effective in decreasing postoperative bleeding of CABG surgery.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] On the other hand, Ovrum <italic>et al</italic>. have shown no significant decrease in blood loss with intravenous TA usage and also have shown possible increased risk of thromboembolic complications including graft closure with antifibrinolytic usage after CABG.[<xref rid="ref15" ref-type="bibr">15</xref>] The concept of using topical usage of antifibrinolytic agents was studied in several trials to prevent possible thromboembolic complications of their intravenous usage and has published decreased postoperative bleeding with topical usage of TA.[<xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref20" ref-type="bibr">20</xref>] Bonis <italic>et al</italic>. poured 1 g TA in 100 mL of saline solution in mediastinal cavity of twenty patients and compared them with twenty control patients and showed significant reduction in postoperative bleeding.[<xref rid="ref18" ref-type="bibr">18</xref>] Fawzy <italic>et al</italic>. compared 19 patients receiving 1 g TA diluted in 100 ml normal saline with 19 control group patients and resulted in significant reduction in postoperative blood loss without adding extra risk to the patients.[<xref rid="ref20" ref-type="bibr">20</xref>] In our study, larger numbers of patients (125 patients) were included and the effectiveness of topical usage of 1 g TA diluted in 100 ml normal saline in preventing post-CABG blood loss was assessed. The amount and concentration of TA used in our study were nearly similar to other studies. The study showed no difference in postoperative blood loss in either first or second 24 h. Furthermore, blood transfusion was not decreased in the study group.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>We do not recommend topical usage of 1 g TA diluted in 100 ml normal saline for decreasing blood loss in on-pump CABG patients. More studies are needed to clear why there are different results of different studies. Furthermore, it is recommended to apply larger amounts of local TA to assess its effectiveness in decreasing postoperative blood loss.</p><sec id="sec2-3"><title>Declaration of patient consent</title><p>The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.</p></sec><sec id="sec2-4"><title>Financial support and sponsorship</title><p>Islamic Azad University Najafabad Branch, Isfahan, Iran.</p></sec><sec id="sec2-5" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge the dedicated efforts of Mrs. Najimeh Tarkesh Esfahani, M. Sc of biostatistics, the volunteer patients who participated in this study, and the Clinical Research Development Unit of Isfahan Sina hospital.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despotis</surname><given-names>GJ</given-names></name><name><surname>Santoro</surname><given-names>SA</given-names></name><name><surname>Spitznagel</surname><given-names>E</given-names></name><name><surname>Kater</surname><given-names>KM</given-names></name><name><surname>Cox</surname><given-names>JL</given-names></name><name><surname>Barnes</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation</article-title><source>J Thorac Cardiovasc Surg</source><year>1994</year><volume>107</volume><fpage>271</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8283896</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinder</surname><given-names>CS</given-names></name><name><surname>Mathew</surname><given-names>JP</given-names></name><name><surname>Rinder</surname><given-names>HM</given-names></name><name><surname>Bonan</surname><given-names>J</given-names></name><name><surname>Ault</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Modulation of platelet surface adhesion receptors during cardiopulmonary bypass</article-title><source>Anesthesiology</source><year>1991</year><volume>75</volume><fpage>563</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">1718190</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucuk</surname><given-names>O</given-names></name><name><surname>Kwaan</surname><given-names>HC</given-names></name><name><surname>Frederickson</surname><given-names>J</given-names></name><name><surname>Wade</surname><given-names>L</given-names></name><name><surname>Green</surname><given-names>D</given-names></name></person-group><article-title>Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation</article-title><source>Am J Hematol</source><year>1986</year><volume>23</volume><fpage>223</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">3766524</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmer</surname><given-names>JH</given-names><suffix>Jr</suffix></name><name><surname>Stanford</surname><given-names>W</given-names></name><name><surname>Bonney</surname><given-names>SL</given-names></name><name><surname>Breen</surname><given-names>JF</given-names></name><name><surname>Chomka</surname><given-names>EV</given-names></name><name><surname>Eldredge</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study</article-title><source>J Thorac Cardiovasc Surg</source><year>1994</year><volume>107</volume><fpage>543</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">7508070</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dacey</surname><given-names>LJ</given-names></name><name><surname>Munoz</surname><given-names>JJ</given-names></name><name><surname>Baribeau</surname><given-names>YR</given-names></name><name><surname>Johnson</surname><given-names>ER</given-names></name><name><surname>Lahey</surname><given-names>SJ</given-names></name><name><surname>Leavitt</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors. Northern New England cardiovascular disease study group</article-title><source>Arch Surg</source><year>1998</year><volume>133</volume><fpage>442</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9565127</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellman</surname><given-names>M</given-names></name><name><surname>Intonti</surname><given-names>MA</given-names></name><name><surname>Ivert</surname><given-names>T</given-names></name></person-group><article-title>Reoperations for bleeding after coronary artery bypass procedures during 25 years</article-title><source>Eur J Cardiothorac Surg</source><year>1997</year><volume>11</volume><fpage>521</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9105818</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RH</given-names></name><name><surname>Sheng</surname><given-names>S</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>SM</given-names></name><name><surname>Grover</surname><given-names>FL</given-names></name><name><surname>Gammie</surname><given-names>JS</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Reoperation for bleeding in patients undergoing coronary artery bypass surgery: Incidence, risk factors, time trends, and outcomes</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2009</year><volume>2</volume><fpage>583</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">20031896</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kevy</surname><given-names>SV</given-names></name><name><surname>Glickman</surname><given-names>RM</given-names></name><name><surname>Bernhard</surname><given-names>WF</given-names></name><name><surname>Diamond</surname><given-names>LK</given-names></name><name><surname>Gross</surname><given-names>RE</given-names></name></person-group><article-title>The pathogenesis and control of the hemorrhagic defect in open heart surgery</article-title><source>Surg Gynecol Obstet</source><year>1966</year><volume>123</volume><fpage>313</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">5913482</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daily</surname><given-names>PO</given-names></name><name><surname>Lamphere</surname><given-names>JA</given-names></name><name><surname>Dembitsky</surname><given-names>WP</given-names></name><name><surname>Adamson</surname><given-names>RM</given-names></name><name><surname>Dans</surname><given-names>NF</given-names></name></person-group><article-title>Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study</article-title><source>J Thorac Cardiovasc Surg</source><year>1994</year><volume>108</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">8028387</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosgrove</surname><given-names>DM</given-names><suffix>3rd</suffix></name><name><surname>Heric</surname><given-names>B</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Taylor</surname><given-names>PC</given-names></name><name><surname>Novoa</surname><given-names>R</given-names></name><name><surname>Golding</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study</article-title><source>Ann Thorac Surg</source><year>1992</year><volume>54</volume><fpage>1031</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1280411</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horrow</surname><given-names>JC</given-names></name><name><surname>Hlavacek</surname><given-names>J</given-names></name><name><surname>Strong</surname><given-names>MD</given-names></name><name><surname>Collier</surname><given-names>W</given-names></name><name><surname>Brodsky</surname><given-names>I</given-names></name><name><surname>Goldman</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Prophylactic tranexamic acid decreases bleeding after cardiac operations</article-title><source>J Thorac Cardiovasc Surg</source><year>1990</year><volume>99</volume><fpage>70</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">2403616</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casati</surname><given-names>V</given-names></name><name><surname>Bellotti</surname><given-names>F</given-names></name><name><surname>Gerli</surname><given-names>C</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Oppizzi</surname><given-names>M</given-names></name><name><surname>Cossolini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tranexamic acid administration after cardiac surgery: A prospective, randomized, double-blind, placebo-controlled study</article-title><source>Anesthesiology</source><year>2001</year><volume>94</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11135716</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casati</surname><given-names>V</given-names></name><name><surname>Guzzon</surname><given-names>D</given-names></name><name><surname>Oppizzi</surname><given-names>M</given-names></name><name><surname>Bellotti</surname><given-names>F</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Gerli</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions</article-title><source>J Thorac Cardiovasc Surg</source><year>2000</year><volume>120</volume><fpage>520</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10962414</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Cromheecke</surname><given-names>ME</given-names></name><name><surname>de Jonge</surname><given-names>E</given-names></name><name><surname>Prins</surname><given-names>MH</given-names></name><name><surname>de Mol</surname><given-names>BJ</given-names></name><name><surname>Bri&#x000eb;t</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints</article-title><source>Lancet</source><year>1999</year><volume>354</volume><fpage>1940</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10622296</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ovrum</surname><given-names>E</given-names></name><name><surname>Am Holen</surname><given-names>E</given-names></name><name><surname>Abdelnoor</surname><given-names>M</given-names></name><name><surname>Oystese</surname><given-names>R</given-names></name><name><surname>Ringdal</surname><given-names>ML</given-names></name></person-group><article-title>Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations</article-title><source>J Thorac Cardiovasc Surg</source><year>1993</year><volume>105</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8419712</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabzi</surname><given-names>F</given-names></name><name><surname>Moradi</surname><given-names>GR</given-names></name><name><surname>Dadkhah</surname><given-names>H</given-names></name><name><surname>Poormotaabed</surname><given-names>A</given-names></name><name><surname>Dabiri</surname><given-names>S</given-names></name></person-group><article-title>Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery(*)</article-title><source>J Res Med Sci</source><year>2012</year><volume>17</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">23248660</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghadavoudi</surname><given-names>O</given-names></name></person-group><article-title>Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery</article-title><source>J Res Med Sci</source><year>2012</year><volume>17</volume><fpage>313</fpage><pub-id pub-id-type="pmid">23267388</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bonis</surname><given-names>M</given-names></name><name><surname>Cavaliere</surname><given-names>F</given-names></name><name><surname>Alessandrini</surname><given-names>F</given-names></name><name><surname>Lapenna</surname><given-names>E</given-names></name><name><surname>Santarelli</surname><given-names>F</given-names></name><name><surname>Moscato</surname><given-names>U</given-names></name><etal/></person-group><article-title>Topical use of tranexamic acid in coronary artery bypass operations: A double-blind, prospective, randomized, placebo-controlled study</article-title><source>J Thorac Cardiovasc Surg</source><year>2000</year><volume>119</volume><fpage>575</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10694619</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleym</surname><given-names>H</given-names></name><name><surname>Stenseth</surname><given-names>R</given-names></name><name><surname>Wahba</surname><given-names>A</given-names></name><name><surname>Bjella</surname><given-names>L</given-names></name><name><surname>Karevold</surname><given-names>A</given-names></name><name><surname>Dale</surname><given-names>O</given-names></name><etal/></person-group><article-title>Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery</article-title><source>Anesth Analg</source><year>2003</year><volume>96</volume><fpage>923</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12651635</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fawzy</surname><given-names>H</given-names></name><name><surname>Elmistekawy</surname><given-names>E</given-names></name><name><surname>Bonneau</surname><given-names>D</given-names></name><name><surname>Latter</surname><given-names>D</given-names></name><name><surname>Errett</surname><given-names>L</given-names></name></person-group><article-title>Can local application of tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial</article-title><source>J Cardiothorac Surg</source><year>2009</year><volume>4</volume><fpage>25</fpage><pub-id pub-id-type="pmid">19538741</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karski</surname><given-names>JM</given-names></name><name><surname>Teasdale</surname><given-names>SJ</given-names></name><name><surname>Norman</surname><given-names>PH</given-names></name><name><surname>Carroll</surname><given-names>JA</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name><name><surname>Glynn</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid</article-title><source>J Cardiothorac Vasc Anesth</source><year>1993</year><volume>7</volume><fpage>431</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8104526</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousou</surname><given-names>JA</given-names></name><name><surname>Engelman</surname><given-names>RM</given-names></name><name><surname>Flack</surname><given-names>JE</given-names><suffix>3rd</suffix></name><name><surname>Deaton</surname><given-names>DW</given-names></name><name><surname>Owen</surname><given-names>SG</given-names></name></person-group><article-title>Tranexamic acid significantly reduces blood loss associated with coronary revascularization</article-title><source>Ann Thorac Surg</source><year>1995</year><volume>59</volume><fpage>671</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7887710</pub-id></element-citation></ref></ref-list></back></article>